Washington Medicaid (Apple Health) GLP-1 Coverage (2026): Pattern #14 — YMYL-Trap / Indication-Anchored Coverage (KFF Lists WA as Covering; HCA's Own Policies Say "Not Covered by Apple Health for Weight Loss" — WAC 182-530-2100(1)(b)(i) + 42 U.S.C. § 1396r-8(d)(2)(A) + MACE/MASH/OSA Carve-Outs Operative Since July 2024)

Washington Apple Health — the state's branded umbrella for Medicaid and CHIP, administered by the Washington State Health Care Authority (HCA) — is the YMYL-trap state of the 50-state Medicaid GLP-1 series: the state that simultaneously appears on the KFF January 2026 “13 covering states” list and publishes the verbatim phrase “is not covered by Apple Health for weight loss” in its own active clinical policies. If you read KFF and concluded that Washington Medicaid covers Wegovy or Zepbound for obesity, you will hit that exact language when you look at the primary source.

The accurate framing is indication-anchored coverage: Washington covers Wegovy and Zepbound — but only for non-weight-loss FDA-approved indications. Wegovy is covered for established cardiovascular disease (MACE reduction, effective July 1, 2024 — over 22 months ago) and for moderate-to-severe noncirrhotic MASH. Zepbound is covered for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Coverage does not attach to the FDA chronic weight management indication. An Apple Health enrollee with BMI 35 and no qualifying cardiovascular disease, MASH, or OSA cannot obtain Wegovy or Zepbound for chronic weight management — regardless of BMI, regardless of body weight trajectory, and regardless of any KFF classification.

TL;DR — What Apple Health covers (and what it does not)

Washington Apple Health covers GLP-1 receptor agonists with prior authorization for the following non-weight-loss FDA-approved indications:

• Wegovy® (semaglutide) for MACE risk reduction: BMI ≥ 27, established cardiovascular disease (prior MI/stroke/symptomatic carotid/CAD/PAD), HbA1c ≤ 6.5% (no T2DM), concurrent CV standard-of-care, no concurrent GLP-1/DPP4. Pathway operative since July 1, 2024 — 22+ months before this article.
• Wegovy® (semaglutide injection) for noncirrhotic MASH: F2/F3 fibrosis confirmed by biopsy or non-invasive scoring (Fib-4, FibroScan, APRI, FibroTest, ARFI/PSWE elastography), age ≥ 18, no T2DM, at least one cardiovascular risk factor.
• Zepbound® (tirzepatide) for obstructive sleep apnea: BMI > 30, AHI/RDI ≥ 15 without PAP, PAP consultation documented, lifestyle interventions ongoing, age ≥ 18, no T2DM, no concurrent GLP-1.
• GLP-1s for type 2 diabetes mellitus (T2DM): Exenatide pen, Bydureon BCISE, and generic liraglutide pen are preferred (PA, age ≥ 10). Ozempic, Rybelsus, Mounjaro, Victoza, and Trulicity are non-preferred (double step-therapy: metformin + liraglutide failure, age ≥ 18).
• Imcivree® (setmelanotide) for rare genetic obesity: POMC, PCSK1, LEPR deficiency, or Bardet-Biedl syndrome only. Preferred (CP) on the AHPDL. Not a chronic-weight-management pathway.

Apple Health does NOT cover any of the following:

• Wegovy or Zepbound for the FDA chronic weight management indication (no qualifying CVD, MASH, or OSA)
• Saxenda (liraglutide 3 mg) — NC/WGHT on the AHPDL
• Foundayo (orforglipron, all six strengths) — NC/WGHT on the AHPDL, pre-emptively excluded at launch
• Compounded semaglutide syringe formulations — NC/NFDA (not FDA-approved, a separate exclusion mechanism from the weight-loss exclusion)
• Qsymia, Contrave, phentermine, orlistat/Xenical/Alli, benzphetamine, diethylpropion, phendimetrazine, Plenity — all NC/WGHT on the AHPDL

The YMYL trap: why KFF says “covering” and HCA says “not covered for weight loss”

KFF's January 16, 2026 Medicaid GLP-1 tracker lists Washington as one of 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service. The 13 states are Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, and Washington. That classification is not wrong — but it is incomplete in a way that creates an acute YMYL hazard for any Apple Health enrollee who reads it without the indication caveat.

The same month that KFF published its tracker, HCA's Medical Policy 61.25.20.AA-4 (Wegovy, effective February 1, 2026) and Policy 61.25.25.AA-1 (Zepbound, effective May 1, 2025) each contain the following sentence:

Semaglutide injection or tablet (Wegovy®) is not covered by Apple Health for weight loss in accordance with:
• WAC 182-530-2100(1)b)(i)
• SEC. 1927. [42 U.S.C. 1396r–8](d)(2)(A)

And for Zepbound:

Tirzepatide (Zepbound®) is not covered by Apple Health for weight loss in accordance with:
• WAC 182-530-2100(1)b)(i)
• SEC. 1927. [42 U.S.C. 1396r–8](d)(2)(A)

These two sentences — verbatim from the operative HCA clinical policies — are the authoritative, dispositive statements about Apple Health obesity coverage. KFF's “covering” classification reflects the fact that Washington's MACE pathway (BMI ≥ 27) and OSA pathway (BMI > 30) use obesity-adjacent BMI thresholds that functionally apply to most adults with obesity who also have one of those conditions. KFF correctly identifies that a coverage pathway exists for those comorbidity-positive subgroups. What KFF's headline classification does not convey — and what the HCA policies say explicitly — is that coverage does NOT attach to chronic weight management as such.

An Apple Health enrollee with BMI 35 and no documented CVD, no biopsy/imaging-confirmed F2/F3 MASH, and no AHI ≥ 15 sleep study will be denied. The denial will cite WAC 182-530-2100(1)(b)(i) and 42 U.S.C. § 1396r-8(d)(2)(A). No amount of BMI documentation, dietitian letters, or primary-care attestations will overcome a denial anchored in those two provisions without a qualifying non-weight-loss indication.

Pattern #14 in the 50-state taxonomy: indication-anchored coverage

Washington is the 14th state in our series and the first to occupy the “indication-anchored coverage with explicit weight-loss exclusion” quadrant — a pattern distinct from every prior state:

Within the taxonomy, Washington is most analogous to New Jersey (#10): both have explicit weight-loss administrative-code exclusions (WAC 182-530-2100(1)(b)(i) vs. N.J.A.C. § 10:51-1.13(a)(2)); both have DURB/HCA-approved Wegovy MACE, MASH, and Zepbound OSA carve-outs; both have active coverage-mandate legislation pending in committee. The distinguishing difference is that KFF classifies WA as a “covering” state while classifying NJ as “not covering.” This illustrates that KFF's surveying methodology treats the BMI ≥ 27 MACE and BMI > 30 OSA pathways as effectively constituting obesity-population coverage — which they do, for the comorbid subset. They do not constitute chronic-weight-management coverage for the comorbidity-free obese member.

Two separate exclusion regimes operating in Washington

Washington has two legally distinct mechanisms that prohibit GLP-1 obesity coverage, and the article must keep them rigorously separate because their reform pathways differ:

Regime 1: WAC 182-530-2100(1)(b)(i) — Apple Health Medicaid (permanent administrative rule)

WAC 182-530-2100 is the Washington Administrative Code rule governing Medicaid drug exclusions. Its most recent amendment was WSR 25-21-142, filed October 21, 2025, effective November 21, 2025. The operative subsection is verbatim:

“(1) The medicaid agency does not cover:

(a) A drug that is:
  (i) Not approved by the Food and Drug Administration (FDA); or
  (ii) Prescribed for a nonmedically accepted indication …

(b) A drug prescribed:
  (i) For weight loss or gain;”

This is a permanent administrative rule, not a year-by-year budget rider. To repeal or modify it, HCA must go through the Washington Administrative Procedure Act's rulemaking process (WSR promulgation, public comment, CR-101/CR-102/CR-103 filing). It cannot be changed by a budget act alone. The weight-loss exclusion at subsection (1)(b)(i) has been continuous since the original WAC 388-530-2100 (September 26, 2007), recodified to WAC 182-530-2100 on June 30, 2011.

The same subsection contains an important exception pathway at subsection (2): “Noncovered drugs may be requested through the exception to rule process per WAC 182-501-0160.” The ETR pathway is the formal channel for an individual member to contest a weight-loss-indication denial, though Apple Health's clinical staff reviews ETR submissions against the member's medical-necessity evidence, and the WAC 182-530-2100(1)(b)(i) exclusion sets a high bar for override.

Regime 2: Laws of Washington 2024, ch. 376, §§ 902-903 — PEBB/SEBB/UMP (year-by-year budget rider)

Entirely separate from Apple Health Medicaid is the prohibition on GLP-1 obesity coverage for the Washington Public Employees Benefits Board (PEBB) and School Employees Benefits Board (SEBB) plans, including the self-insured Uniform Medical Plan (UMP) administered by Moda as PBM. Per the HCA fiscal note for SB 5353 (February 17, 2025):

“Currently, all PEBB and SEBB plans … do not provide coverage of GLP-1s for the treatment of obesity; such coverage is expressly prohibited in the current state operating budget unless there is a specific appropriation from the legislature (Laws of Washington 2024, ch. 376, §§ 902-903).”

The 2024 budget rider is a year-by-year mechanism: the Legislature can lift it through a specific appropriation in a future budget act without needing WAC rulemaking. This is structurally easier to reverse than the Apple Health WAC exclusion — but as of May 10, 2026, the Legislature has not made that appropriation. SB 5353 (see Section 12) would impose a coverage mandate on both regimes simultaneously.

PEBB/SEBB members (Washington state employees, school employees, and their dependents) are NOT on Apple Health Medicaid. The coverage pathways described in this article for Apple Health do not apply to UMP or any PEBB/SEBB plan. A Washington state employee on UMP cannot use the Wegovy MACE or Zepbound OSA pathways documented here — their benefit is governed by Moda, not HCA FFS.

Wegovy for MACE risk reduction — the original indication-anchored carve-out (effective July 1, 2024)

Washington's Wegovy MACE pathway is 22+ months old as of May 2026 — making it the oldest indication-anchored carve-out in the entire 50-state series. Ohio's analogous carve-out was created by the January 7, 2026 P&T Committee meeting. Washington created its version in the HCA-internal approval dated July 1, 2024. The policy has since been revised three times (version 2 effective 5/1/2025; version 3 effective 12/1/2025; version 4 effective 2/1/2026), with the latest version adding Wegovy tablets.

The operative criteria from HCA Medical Policy 61.25.20.AA-4 (effective February 1, 2026), verbatim:

“Semaglutide injection or tablet (Wegovy®) may be approved when all the following documented criteria are met:
1. Patient has BMI ≥ 27 kg/m²; AND
2. Patient is ≥ 18 years of age or older; AND
3. Patient does not have diabetes or HgA1C > 6.5% (patients with T2DM or A1C > 6.5 should request GLP-1 indicated for T2DM, see policy 27.17.00); AND
4. Patient has established cardiovascular disease with one or more of the following:
  a. Prior stroke (ischemic or hemorrhagic); OR
  b. Prior myocardial infarction (MI); OR
  c. Symptomatic carotid artery disease… [stenosis > 50%; revascularization; TIA]; OR
  d. Symptomatic coronary artery disease… [stenosis ≥ 50%; angina; prior revascularization]; OR
  e. Symptomatic peripheral arterial disease (PAD)… [claudication with ABI < 0.85; revascularization; amputation]; AND
5. Treatment plan includes concurrent use of antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel, cangrelor); OR antihypertensive therapy; OR lipid-lowering therapy, unless contraindicated; AND
6. Semaglutide will not be used in combination with another GLP-1 receptor agonist or DPP4 inhibitor.

If ALL criteria are met, the request will be authorized for 6 months.”

Reauthorization criteria (verbatim):

“Semaglutide injection or tablet (Wegovy®) may be approved when all the following documented criteria are met:
1. Member has received previous authorization approval or has been established on therapy from another health plan (excludes establishing therapy from use of samples, patient assistance programs, or coupons); AND
2. Patient continues to meet criteria 2–6 above.

If ALL criteria are met, the request will be authorized for 12 months.”

Critical operational note: reauthorization explicitly drops criterion 1 (BMI ≥ 27). Once a member is established on Wegovy MACE and has received a prior authorization, continuity of therapy does not require re-documenting BMI at the ≥ 27 threshold. This is the same pattern as the NY DUR Wegovy MACE pathway — distinct from the PA/OH weight-loss reauthorization approaches that require a 5% weight-loss-from-baseline milestone.

WA's Wegovy MACE BMI threshold (BMI ≥ 27) is also more permissive than NY's DUR pathway (BMI ≥ 40). An Apple Health member with BMI 28 and a prior MI qualifies under HCA Policy 61.25.20.AA-4. A NYRx member with the same profile at BMI 28 does not qualify for the DUR carve-out.

Wegovy® formulations covered under this pathway (AHPDL May 9-15, 2026, PA Policy 612520AA, MCO Carve Out = Y, Coverage Type CP):

Wegovy is listed as non-preferred (N) at the AHPDL pharmacy level. This does not bar coverage; it means the PA pathway applies (all MACE/MASH criteria must be documented). Wegovy HD (7.2 mg/0.75 mL) — the 2026 Novo Nordisk high-dose launch — is on the AHPDL under the same PA policy. Wegovy tablets (1.5/4/9/25 mg) were added effective February 1, 2026.

Wegovy for noncirrhotic MASH — the hepatic pathway (injection only)

HCA Medical Policy 61.25.20.AA-4 covers Wegovy injection (not tablets) for moderate-to-severe (F2/F3) noncirrhotic MASH. Verbatim criteria:

“Treatment of moderate to severe (F2 or F3) noncirrhotic metabolic dysfunction associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), in adults

Semaglutide injection (Wegovy®) may be approved when all the following documented criteria are met:
1. Patient is ≥ 18 years of age or older; AND
2. Patient does not have diabetes or HgA1C > 6.5%; AND
3. Patient has a diagnosis of moderate to severe MASH (Fibrosis stage F2 and F3) confirmed by the following:
  a. biopsy; OR
  b. Fib-4 score 1.3 to 3.48; OR
  c. Fibroscan score 8.5–13.5 kPA; OR
  d. APRI 1.0–1.9; OR
  e. Fibrotest 0.49–0.74; OR
  f. Elastography (ARFI/PSWE) 1.38–2.33 m/s; AND
4. One or more cardiovascular risk factors listed in appendix A below.

If ALL criteria are met, the request will be authorized for 6 months.”

Appendix A cardiovascular risk factors (verbatim):

“Cardiovascular Risk Factors include (but not limited to):
• Chronic kidney disease   • Obesity BMI ≥ 30 kg/m²
• Dyslipidemia   • Prediabetes
• Hypertension”

Note that “Obesity BMI ≥ 30” is listed as one of the qualifying cardiovascular risk factors. This creates a practical overlap: a member with confirmed F2/F3 MASH and BMI ≥ 30 (and no other cardiovascular condition) qualifies for Wegovy MASH coverage on that basis alone. This is an indirect pathway to coverage for obese patients with liver disease. It is not a chronic-weight-management pathway; it is a hepatic-disease pathway for which the weight-loss exclusion does not apply.

MASH reauthorization criteria (verbatim):

“Semaglutide injection (Wegovy®) may be approved when all the following documented criteria are met:
1. Member has received previous authorization approval or has been established on therapy from another health plan (excludes establishing therapy from use of samples, patient assistance programs, or coupons); AND
2. Patient continues to meet criteria 1–4 above; AND
3. Patient does not have cirrhosis for fibrosis score > F3.

If ALL criteria are met, the request will be authorized for 12 months.”

Comparing WA's MASH pathway to the 50-state cluster: WA's non-invasive scoring options (five FibroScan/APRI/Fibrotest/ARFI alternatives to biopsy) represent a relatively accessible evidence standard. PA's MASH pathway requires ELF score and age-stratified FIB-4 thresholds. CA's April 2026 MASH pathway is MASH-only — WA had the MASH carve-out operational a full year before CA's reinstatement. OH's MASH pathway requires biopsy-confirmed or imaging-confirmed F2/F3 plus lifestyle modifications and optimized care for concomitant conditions.

Zepbound for obstructive sleep apnea — and the vial-formulation note

HCA Medical Policy 61.25.25.AA-1 (effective May 1, 2025) covers tirzepatide (Zepbound) for moderate-to-severe OSA. Verbatim criteria:

“Tirzepatide (Zepbound) may be approved when all of the following documented criteria are met:
1. Patient is ≥ 18 years of age; AND
2. Patient does not have diabetes or HbA1C > 6.5% (patients with T2DM or A1C > 6.5 should request GLP-1 indicated for T2DM, see policy 27.17.00); AND
3. Provider attestation that patient has moderate to severe obstructive sleep apnea as defined as AHI or RDI ≥ 15 obstructive respiratory events per hour (apneas, hypopneas, or RERAs), without the use of a positive airway pressure device (PAP); AND
4. Patient meets one of the following criteria:
  a. The patient was consulted about use of PAP; AND
  b. Declined use of PAP; OR
  c. Unable to tolerate PAP therapy; OR
  d. Actively using PAP and will continue to use PAP; AND
5. Patient is engaged in lifestyle interventions including diet, exercise, and behavioral modification; AND
6. Tirzepatide will not be used in combination with another GLP-1 agonist; AND
7. Patient has a body mass index (BMI) > 30 kg/m²

If ALL criteria are met, the request will be authorized for 6 months.”

Reauthorization criteria (verbatim):

“Tirzepatide (Zepbound®) may be reauthorized when all the following documented criteria are met:
1. Member has received previous authorization approval or has been established on therapy from another health plan (excludes establishing therapy from use of samples, patient assistance programs, or coupons); AND
2. Patient continues to meet criteria 1–6 above; AND
3. Documentation is submitted demonstrating a positive clinical response [e.g., weight loss, fewer AHIs per hour of sleep, or improved systolic blood pressure].

If ALL criteria are met, the request will be authorized for 12 months.”

Important nuance in reauthorization criterion 3: weight loss is listed as one of three acceptable markers of positive clinical response for the OSA treatment. Weight loss in this context is a measure of effectiveness of a drug approved for OSA — it is not the covered indication. The coverage indication remains OSA. An Apple Health member who loses weight while on Zepbound OSA is not converted to a weight-loss-indication patient; their authorization continues under the OSA carve-out.

Zepbound is listed as preferred (P) at the AHPDL pharmacy level — the opposite of Wegovy (non-preferred). This is the only state in the series where Zepbound has a higher preference status than Wegovy for non-obesity indications; the AHPDL architecture suggests HCA has a more favorable supplemental-rebate position for Zepbound under the OSA indication.

Zepbound formulations covered (AHPDL May 9-15, 2026, PA Policy 612525AA, MCO Carve Out = Y, Coverage Type CP, Pharmacy Preferred P):

The Zepbound single-use vial formulations (2.5/5/7.5/10/12.5/15 mg) are on the AHPDL under the same OSA PA Policy (612525AA). The vials are a lower-cost LillyDirect cash-pay product in the commercial market. Under Apple Health, the vials are covered through the same OSA clinical pathway as the pen and KwikPen formulations — not as a cash-pay bypass. Members should not assume that using the vial formulation avoids the PA requirement; it does not.

Imcivree (setmelanotide): the only weight-management AOM covered without a non-weight-loss anchor

Imcivree (setmelanotide acetate, 10 mg/mL vial) is listed on the AHPDL as Coverage Type CP (Covered with PA), Pharmacy Preferred Status P (Preferred), MCO Carve Out = Y. It is the only anti-obesity agent on Apple Health that carries coverage under a weight-loss indication — because the FDA approved setmelanotide specifically for chronic weight management in adults and children ≥ 6 with confirmed POMC deficiency, PCSK1 deficiency, LEPR deficiency, or Bardet-Biedl syndrome.

The genetic-obesity carve-out for Imcivree is not a backdoor pathway for general chronic-weight-management coverage. These four conditions are rare (estimated 5,000–50,000 U.S. patients total). They require confirmed genetic testing — a biopsy of the WAC 182-530-2100(1)(b)(i) exclusion is not possible without a genetic diagnosis meeting one of those four specific syndromes. The median Apple Health enrollee with obesity does not qualify.

Pre-emptively excluded: Foundayo and compounded semaglutide

Foundayo (orforglipron) — all six strengths excluded

Foundayo (orforglipron calcium tablet), the Eli Lilly oral GLP-1 receptor agonist approved by the FDA in late 2025 for the chronic weight management indication, is listed on the AHPDL May 9-15, 2026 with Coverage Type = NC, Non-Covered Reason = WGHT for all six FDA-approved strengths (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg tablets). HCA extended the WAC 182-530-2100(1)(b)(i) weight-loss exclusion to Foundayo at the time of its launch — a pre-emptive coverage decision that mirrors the pre-existing Saxenda/Qsymia/Contrave/phentermine exclusion regime. HCA's revealed preference is that any new FDA-approved drug for the chronic-weight-management indication will be assigned NC/WGHT at launch absent a legislative or regulatory change.

Compounded semaglutide — a separate exclusion mechanism

Compounded semaglutide syringe formulations appear on the AHPDL as Coverage Type = NC, Non-Covered Reason = NFDA (not FDA approved), not WGHT (weight). This is a distinct exclusion layer. Compounded semaglutide is excluded under WAC 182-530-2100(1)(a)(i) — “A drug that is not approved by the Food and Drug Administration” — rather than subsection (1)(b)(i)'s weight-loss exclusion.

The practical consequence: even if SB 5353 were enacted and Apple Health were required to remove the weight-loss exclusion at WAC 182-530-2100(1)(b)(i), compounded semaglutide would still be non-covered under subsection (1)(a)(i) until the FDA approves it as a drug. The two exclusions are independent. Telehealth providers that dispense compounded semaglutide have no coverage pathway through Apple Health regardless of the outcome of the weight-loss-indication reform debate.

Type 2 diabetes pathway — not obesity coverage

Apple Health covers GLP-1 receptor agonists for T2DM under HCA Medical Policy 27.17.00-3 (effective December 1, 2025). Verbatim preferred criteria:

“Type 2 Diabetes without OSA or MASH.
Preferred GLP-1 Agonists may be approved when all of the following documented criteria are met:
1. Diagnosis of type 2 diabetes or an HbA1c ≥ 6.5 within the last 12 months; AND
2. The patient meets the appropriate age limit for the requested product:
  a. Dulaglutide, exenatide, and liraglutide ≥ 10 years old;
  b. Semaglutide and tirzepatide ≥ 18 years old; AND
3. Drug will not be used in combination with another GLP-1 agonist or DPP4 inhibitor.”

Non-preferred GLP-1 PA (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity) verbatim:

“Non-preferred GLP-1 Agonists may be approved when all of the following documented criteria are met:
1. Criteria 1–3 above is met; AND
2. The patient has history of failure, defined as inability to achieve an HbA1c of < 7%, using BOTH of the following separately or simultaneously for a minimum of 90 continuous days unless not tolerated, contraindicated, or clinically inappropriate:
  a. Metformin at maximum or highest tolerated dose; AND
  b. Liraglutide at maximum or highest tolerated dose.

If ALL criteria are met, the request will be authorized for 12 months.”

WA's antidiabetic step-therapy is a double step: both metformin AND liraglutide failure are required before Ozempic/Mounjaro/Rybelsus can be authorized. This is more restrictive than NY (metformin alone) and AZ (metformin alone with HbA1c ≥ 8.5% carve-back-in). A T2DM patient on Apple Health should expect to establish therapy on a preferred agent (exenatide pen, Bydureon BCISE, or generic liraglutide) before qualifying for a branded semaglutide or tirzepatide product.

There is one T2DM MACE carve-back-in for Ozempic specifically. Verbatim:

“Patients with T2DM and established cardiovascular disease or multiple cardiovascular risk factors who are at risk for major adverse cardiovascular events

Semaglutide (Ozempic) may be approved when all the following documented criteria are met:
…5. Patients BMI is 27–30 kg/m²
  a. The patient has history of failure, defined as inability to achieve an HbA1c of < 7%, using the maximum tolerated dose of liraglutide for a minimum of 90 continuous days …
  b. Patients with BMI > 30 kg/m² do not require prior use of liraglutide.”

A T2DM patient with established CVD and BMI > 30 can access Ozempic on the MACE pathway with NO liraglutide step requirement. This is a meaningful carve-back-in for the diabetic-cardiac population. It does not extend to Mounjaro, Rybelsus, or Victoza.

MCO carve-out architecture — why your managed-care plan does not matter for this question

Apple Health is delivered through five contracted MCOs as of contract year 2026: Coordinated Care of Washington (Centene/Ambetter), Molina Healthcare of Washington, UnitedHealthcare Community Plan of Washington, Community Health Plan of Washington (CHPW), and Wellpoint Washington (Elevance/Anthem). For most pharmacy benefits, the MCO adjudicates the claim.

For Wegovy, Zepbound, Saxenda, Foundayo, Imcivree, and compounded semaglutide, the AHPDL marks the entire NEUROLOGICAL AGENTS : ANOREXIANTS / ANTI-OBESITY – GLP-1 RECEPTOR AGONISTS class with MCO Carve Out = Y. This means the FFS HCA pharmacy benefit (not the MCO) processes the claim. A Molina member, a Coordinated Care member, and an unmanaged FFS member are all adjudicated through the same HCA clinical policies. Which of the five MCOs an Apple Health enrollee is assigned to does not affect their Wegovy or Zepbound PA outcome.

Coordinated Care's published WA.PHAR.122 policy (effective December 1, 2025) confirms the deferral:

“Antidiabetics – GLP-1 Agonists
WA.PHAR.122  Effective Date: 12/1/2025

Note: New-to-market drugs included in this class based on the Apple Health Preferred Drug List are non-preferred and subject to this prior authorization (PA) criteria. Non-preferred agents in this class require an inadequate response or documented intolerance due to severe adverse reaction or contraindication to at least TWO preferred agents. If there is only one preferred agent in the class documentation of inadequate response to ONE preferred agent is needed. If a drug within this policy receives a new indication approved by the Food and Drug Administration (FDA), medical necessity for the new indication will be determined on a case-by-case basis following FDA labeling.”

The P&T/DUR Committee (HCA's pharmacy governance body) uses the Prime Therapeutics market basket as the drug-class consultation input. Per the October 15, 2025 P&T/DUR transcript: “the words in purple on the top are the Prime Therapeutic Market Basket, and then below in blue are the Apple Health PDL drug classes.” HCA's P&T makes the final preferred/non-preferred determinations; Prime is the drug-class consultant. This is structurally separate from the UMP/PEBB/SEBB PBM arrangement (Moda).

SB 5353 / HB 1326 — the “Diabetes prevention and obesity treatment act” (still in committee)

The active Washington legislation most relevant to Apple Health GLP-1 obesity coverage is Senate Bill 5353 (S-0547.1) and its companion House Bill 1326, introduced in the 69th Legislature (2025 Regular Session) and reintroduced in the 2026 session. Sponsors: Senators Cleveland, Muzzall, Riccelli, Bateman, Frame, Hasegawa, Krishnadasan, Nobles, Valdez, and C. Wilson.

Legislative history (verbatim):

“Jan 17, 2025: First reading, referred to Health & Long-Term Care.
Feb 4, 2025: Public hearing held in Senate Committee on Health & Long-Term Care.
Jan 12, 2026: Reintroduced by resolution and retained in present status.”

As of May 10, 2026, SB 5353 remains in Senate Committee on Health & Long-Term Care. It has been pre-filed in two consecutive sessions (2025, then reintroduced 2026) without floor action. This article does not predict when or whether the bill will advance.

The Apple Health coverage mandate is in Section 3, verbatim:

“NEW SECTION. Sec. 3. A new section is added to chapter 74.09 RCW to read as follows:

(2) Upon federal authorization, the authority and all managed care organizations shall provide coverage to provide treatment of the chronic disease of obesity including, but not limited to:
  (a) Intensive health behavioral and lifestyle treatment;
  (b) Metabolic and bariatric surgery; and
  (c) Food and drug administration-approved obesity medication.

(3) Coverage criteria for food and drug administration-approved obesity medications may not be more restrictive than the food and drug administration-approved indications for those treatments.”

Subsection (3) is the operationally critical provision: it would prohibit PA criteria more restrictive than the FDA label — which would require HCA to remove the WAC 182-530-2100(1)(b)(i) exclusion and eliminate the AHPDL NC/WGHT designation for Saxenda, Foundayo, Qsymia, Contrave, and phentermine.

The HCA fiscal note (Request #25-058, February 17, 2025, prepared by Samuel Quartey) projects the consequences:

“Apple Health:
The fiscal impact is indeterminate but is expected to be significant.
…
HCA assumes that as drafted, the bill would require coverage of all FDA approved drugs and would be unable to leverage the preferred drug list (PDL) to include preferred AOMs in any future formulary.”

The PDL-leverage statement is significant: if SB 5353's subsection (3) prohibition on “more restrictive than FDA indications” criteria is interpreted to also bar preferred-drug-list step-therapy requirements, HCA would lose the ability to use rebate-maximizing PDL architecture for any anti-obesity drug class. This is the cost driver behind the “indeterminate but significant” Apple Health claims-liability estimate.

The federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

Both HCA's Wegovy and Zepbound clinical policies cite the federal optional-exclusion authority verbatim. The relevant enumerated list from 42 U.S.C. § 1396r-8(d)(2) (verified at Cornell LII) reads in full:

“The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted:

(A) Agents when used for anorexia, weight loss, or weight gain.
(B) Agents when used to promote fertility.
(C) Agents when used for cosmetic purposes or hair growth.
(D) Agents when used for the symptomatic relief of cough and colds.
(E) Prescription vitamins and mineral products, except prenatal vitamins and fluoride preparations.
(F) Nonprescription drugs …
(G) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee.
(H) Agents when used for the treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration.”

Subsection (A) is permissive, not mandatory: it permits state Medicaid programs to exclude agents when used for weight loss but does not require them to do so. The 13 KFF-classified covering states have elected not to exercise this option. Washington — along with the majority of states — elects to exercise it through WAC 182-530-2100(1)(b)(i).

One structural note: WAC 182-530-2100(1)(c) cross-references “section 1927(d)(2)(K) of the Social Security Act” for sexual/erectile-dysfunction drug exclusions. The Cornell-verified text of 42 U.S.C. § 1396r-8(d)(2) enumerates only (A) through (H). There is no subsection (K) in the current federal statute. This WAC cross-reference anomaly is a state-administrative-code artifact that does not affect the chronic-weight-management exclusion at WAC 182-530-2100(1)(b)(i), which is independently anchored at the federal (A) provision.

Understanding the KFF classification — why two authoritative sources appear to contradict

The KFF January 16, 2026 Medicaid GLP-1 tracker and the HCA's own clinical policies appear to say opposite things about Washington. They do not actually contradict — they measure different things:

• KFF measures: Does the state Medicaid program have a coverage pathway for Wegovy or Zepbound for a population that overlaps with obesity? Answer for WA: yes (MACE at BMI ≥ 27; OSA at BMI > 30). KFF classifies WA as “covering.”
• HCA measures: Does coverage attach to the FDA chronic-weight-management indication as such? Answer: no. HCA's own policies state verbatim “not covered by Apple Health for weight loss.”

The accurate statement that reconciles both: Washington Apple Health covers Wegovy and Zepbound for non-weight-loss FDA indications (cardiovascular risk reduction, MASH, OSA) at BMI thresholds that overlap with obesity, but does not cover either drug for the FDA chronic weight management indication.

The YMYL hazard arises when this distinction is lost. A benefits navigator, a telehealth intake clinician, or a Reddit post that relies on KFF's “covers” classification without the indication caveat will mislead Apple Health members into submitting PAs that will be denied. The denial will cite WAC 182-530-2100(1)(b)(i) and 42 U.S.C. § 1396r-8(d)(2)(A). The member will have been misled by a technically-true-but-operationally-incomplete summary.

Where Washington fits in the 50-state cluster

• Vs. Ohio: OH's Wegovy MACE/MASH carve-out was created at the January 7, 2026 P&T meeting. WA had the same carve-out since July 1, 2024 — 18 months earlier. WA also covers Zepbound OSA; OH does not as of May 2026. WA's MACE BMI threshold (BMI ≥ 27) is identical to OH's but WA has no T1D/T2D carve-out (OH explicitly excludes T1D/T2D from MACE; WA uses HbA1c ≤ 6.5% as the practical gate but the policy wording differs). WA is the original architect of the indication-anchored pattern that OH adopted.
• Vs. California: CA reinstated Wegovy MASH coverage on April 1, 2026. WA had Wegovy MASH operative since May 1, 2025 — a full year earlier. WA additionally covers Zepbound OSA; CA does not as of May 2026. Both states have active reform legislation; WA's SB 5353 is older and further from floor action.
• Vs. New Jersey: NJ is the structurally closest analog: dual-authority exclusion (N.J.A.C. § 10:51-1.13(a)(2) for NJ; WAC 182-530-2100(1)(b)(i) for WA); three DURB/HCA carve-outs (MACE, MASH, OSA); active coverage-mandate legislation in committee. Critical difference: KFF classifies WA as “covering” and NJ as “not covering” despite mechanically identical architecture — WA's BMI thresholds are lower (BMI ≥ 27 MACE vs. NJ's BMI ≥ 27) but the KFF methodology evidently weights the OSA pathway and MACE pathway together to reach a “covering” classification for WA.
• Vs. New York: NY has a Wegovy MACE DUR carve-out but at BMI ≥ 40 (WA is BMI ≥ 27, far more permissive). NY does not cover Wegovy MASH or Zepbound OSA. WA is operationally broader than NY for non-weight-loss indications.
• Vs. IL/GA/AZ: All three have NO non-weight-loss GLP-1 carve-outs. WA is structurally far broader.
• Vs. NC (Pattern #12): NC is the only full-positive-coverage state in the cluster (Wegovy Preferred for chronic weight management). WA never had chronic-weight-management coverage. PA terminated 34 months of prior coverage; WA never covered it in the first place. The exclusion at WAC 182-530-2100(1)(b)(i) predates any GLP-1 obesity approval.

Who cannot get Wegovy or Zepbound on Apple Health

• Any Apple Health member with obesity (BMI ≥ 30) and no qualifying CVD, MASH, or OSA diagnosis — categorically excluded by WAC 182-530-2100(1)(b)(i). No PA pathway exists for the chronic-weight-management indication.
• Apple Health members with type 2 diabetes seeking Wegovy MACE/MASH or Zepbound OSA — both clinical policies explicitly redirect T2DM patients to policy 27.17.00 (antidiabetic pathway). A member with T2DM + CVD should pursue the Ozempic T2DM MACE pathway (policy 27.17.00-3), not the Wegovy MACE pathway (policy 61.25.20.AA-4).
• Members seeking Saxenda, Foundayo, compounded semaglutide, Qsymia, Contrave, phentermine, orlistat, Plenity — all NC on the AHPDL (WGHT or NFDA). No PA pathway.
• PEBB/SEBB/UMP members — separate legal regime. Not Apple Health Medicaid. The pathways in this article do not apply.
• Members aged under 18 — both Wegovy MACE/MASH and Zepbound OSA policies require age ≥ 18. Preferred antidiabetic GLP-1s (exenatide, liraglutide, dulaglutide) are available for T2DM at age ≥ 10.

What to do now: a practical checklist for Apple Health members

1. Confirm your comorbidities first. If you have any of the following, a covered non-weight-loss pathway may exist: prior MI or stroke; symptomatic carotid artery disease, coronary artery disease, or PAD; confirmed F2/F3 MASH by biopsy or non-invasive score; or AHI/RDI ≥ 15 on a sleep study. Without one of these, there is no Apple Health pathway for Wegovy or Zepbound regardless of BMI.
2. If you have T2DM, start with the preferred antidiabetic GLP-1 agents (exenatide pen, Bydureon BCISE, generic liraglutide pen) rather than requesting Ozempic or Mounjaro first. The double-step requirement (metformin + liraglutide failure) applies to non-preferred agents. If you have T2DM plus established CVD and BMI > 30, ask your prescriber about the Ozempic MACE pathway under policy 27.17.00-3 (single step waived at BMI > 30).
3. For Wegovy MACE/MASH or Zepbound OSA, ensure your prescriber submits a PA through HCA FFS (not through your MCO). The PA policy numbers are 612520AA (Wegovy) and 612525AA (Zepbound). Your MCO does not adjudicate these claims — HCA does.
4. If denied for weight-loss indication: You may request an Exception to Rule (ETR) per WAC 182-501-0160. The ETR is a formal mechanism to contest a WAC-anchored denial. ETR submissions are reviewed by HCA Pharmacy/HCS clinical staff. If the ETR is denied, you may request a Fair Hearing through the Washington Office of Administrative Hearings (OAH) per WAC 182-526. OAH adjudicates Apple Health denials de novo. Legal aid organizations — Northwest Justice Project and Columbia Legal Services — represent Apple Health members in OAH hearings at no cost.
5. If OAH denies, judicial review is available in Thurston County Superior Court under the Washington Administrative Procedure Act (RCW 34.05). Realistic scope: most members denied for the weight-loss indication will not prevail on OAH or judicial review because the WAC exclusion is facially valid and the federal permissive authority is clear. The most viable path to chronic-weight-management coverage is legislative (SB 5353/HB 1326) rather than administrative appeal.

Related research

For the series context, see our prior 50-state Medicaid GLP-1 articles:

• Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + the January 2026 Wegovy MACE/MASH carve-back-in — the closest structural analog to Washington in the series. OH adopted the Wegovy MACE/MASH carve-out in January 2026; WA pioneered the same pattern 18 months earlier (July 2024). OH has a stricter T1D/T2D exclusion from the MACE pathway; WA uses the HbA1c ≤ 6.5% gate. OH does not cover Zepbound OSA; WA does.
• California Medi-Cal GLP-1 coverage (2026): the policy reversal — CA reinstated Wegovy MASH only in April 2026, a full year after WA had the same pathway operative. WA additionally covers Zepbound OSA (CA does not as of May 2026) and had Wegovy MACE since July 2024. WA is the broadest non-weight-loss-indication state in the 14-state cluster.
• New Jersey Medicaid GLP-1 coverage (2026): dual-authority explicit exclusion + DMAHS fiscal memo — the structurally closest analog to WA: both have administrative-code weight-loss exclusions, three non-weight-loss carve-outs (MACE/MASH/OSA), and active coverage-mandate legislation in committee. Key difference: KFF classifies WA as “covering” and NJ as “not covering” despite near-identical architecture. NJ has the only state Medicaid program with a DMAHS-published dollar-quantified fiscal memo.
• North Carolina Medicaid GLP-1 coverage (2026): Pattern #12 — the first full-coverage state in the cluster — the structural inverse of WA. NC completed a full on-off-on cycle for chronic weight management and as of December 12, 2025 has Wegovy listed as Preferred for the chronic-weight-management indication. WA has never covered chronic weight management. Both states illustrate that the KFF “covering vs. not covering” binary conceals substantial within-group heterogeneity.
• GLP-1 insurance coverage: Medicare, Medicaid, and commercial — the hub article for the 50-state series. Covers the Medicare Part D statutory exclusion, the federal permissive-exclusion authority at 42 U.S.C. § 1396r-8(d)(2)(A), and the full 14-state taxonomy.
• GLP-1 side effect questions answered — for Apple Health members who are approved for Wegovy MACE, MASH, or Zepbound OSA and want primary-source guidance on managing nausea, GI symptoms, and titration-phase side effects.
• Maryland Medicaid GLP-1 coverage (2026): Pattern #17 — regulatory exclusion + dual-indication carve-out via HCPCS J3490 medical benefit — the closest structural analog to WA in the 17-state series on the Wegovy side: both have explicit administrative-code weight-loss exclusions (COMAR 10.09.03.05(A)(14) and WAC 182-530-2100(1)(b)(i)) plus active Wegovy MACE and MASH carve-outs. Key differences: MD does not cover Zepbound for OSA (WA does); MD reimburses Wegovy via HCPCS J3490 medical-benefit per-invoice rather than retail pharmacy PDL; MD’s pending legislation is an “Authorization” enabling statute in conference committee (farther along than WA’s mandate in committee); KFF classifies WA as covering but not MD, despite near-identical Wegovy-indication portfolios.
• Massachusetts Medicaid (MassHealth) GLP-1 coverage (2026): two-phase termination policy-reversal — MA’s Phase 2 coverage architecture (effective July 1, 2026) converges nearly exactly with Washington’s indication-anchored pattern: MACE at BMI ≥ 27, MASH at F2/F3 fibrosis, Zepbound OSA at BMI ≥ 30 and AHI ≥ 15. The structural difference: WA has been indication-anchored continuously since July 2024; MA covered chronic weight management from January 2024 through June 30, 2026 and is transitioning into WA’s architecture. The procedural comparison illuminates how two states arriving at the same post-July 2026 coverage architecture took opposite prior-history paths.